KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Tax Provisions (2017 - 2025)

Sarepta Therapeutics has reported Tax Provisions over the past 9 years, most recently at $4.6 million for Q4 2025.

  • Quarterly results put Tax Provisions at $4.6 million for Q4 2025, down 64.69% from a year ago — trailing twelve months through Dec 2025 was $11.2 million (down 56.7% YoY), and the annual figure for FY2025 was $11.2 million, down 56.62%.
  • Tax Provisions for Q4 2025 was $4.6 million at Sarepta Therapeutics, up from -$14.1 million in the prior quarter.
  • Over the last five years, Tax Provisions for SRPT hit a ceiling of $64.0 million in Q1 2025 and a floor of -$43.3 million in Q2 2025.
  • Median Tax Provisions over the past 5 years was $2.4 million (2022), compared with a mean of $3.3 million.
  • Biggest five-year swings in Tax Provisions: soared 8528.26% in 2022 and later plummeted 3669.62% in 2025.
  • Sarepta Therapeutics' Tax Provisions stood at $92000.0 in 2021, then soared by 8528.26% to $7.9 million in 2022, then crashed by 164.49% to -$5.1 million in 2023, then soared by 353.64% to $13.0 million in 2024, then crashed by 64.69% to $4.6 million in 2025.
  • The last three reported values for Tax Provisions were $4.6 million (Q4 2025), -$14.1 million (Q3 2025), and -$43.3 million (Q2 2025) per Business Quant data.